5 / 11
Page 16
Notes:
allied
academies
Journal of Medical Oncology & Therapeutics | Volume 4
March 18-19, 2019 | London, UK
Oncology & Cancer Therapy
International Conference on
C
hemotherapy induced peripheral neuropathy (CIPN) is
debilitating pain condition that results from the use of
anticancer drugs such as taxanes, platinum compounds
vinca alkaloids, and the like. At present, CIPN is being
managed, albeit poorly, with diverse drugs comprising
opioids, cannabinoids, anti-epileptics, and antidepressants.
Our extensive work on pentacyclic pyridoindole scaffolds
resulted in identification of such an analgesic, DDD-028 (1a),
for the potential treatment of
CIPN. DDD-028 displays potent
analgesic activity in paclitaxel
induced neuropathy (CIPN).
The in vivo study involving
chronic
administration
of
paclitaxel along with DDD-
028 over an 18-day period
demonstrated that DDD-028 is
exerting a prophylactic effect
against CIPN. Tissue analysis of
the spinal cord and the key areas of the brain demonstrates
that DDD-028 is preventing the nerve damage by inhibiting
glial cell proliferation and changes in morphology. In the
receptor binding and selected functional studies, DDD-028
showed no activity at any of the opioid, cannabinoid, or
dopamine receptors. DDD-028 is well tolerated in all of the
tests and does induce any sedation in any of the animals.
Speaker Biography
Raghavan Rajagopalan is Founder and Chief Scientific Officer of Daya Drug Discoveries
Inc., and its affiliate Daya CNS, LLC. He received his PhD in Organic Chemistry from
Columbia University in New York, NY, B.S. in Chemistry from State University of New
York, Stony Brook, NY, a graduate certificate in Applied Mathematics from Washington
University in St. Louis, MO. He did his post-doctoral research in immunochemistry the
department of microbiology, Columbia University, New York NY. He is an innovative
organic/medicinal chemist and a Registered Patent Agent with the United States Patent
& Trademark Office. He has over 35 years of experience in diagnostic and therapeutic
drug discovery and developmental research related to four key areas: oncology,
neuroscience, nephrology, and infectious diseases. During that time, he has been
engaged in small molecules drug discovery in cancer phototherapy, chronic kidney
disease, pain, drug addiction, and ADHD. He is principally responsible for the chemistry
section for IND and NDA application for 4 drug candidates, 1 of which approved and
commercialized with another one undergoing Phase 2 clinical trials. He has over 100
patents and 52 professional publications and presentations of which 3 are landmark
publications in kidney disease and cancer phototherapy.
e:
raghavanr@daya-dd.comRaghavan Rajagopalan
Daya Drug Discoveries, USA
Disease modifying non-opioid analgesic for chemotherapy induced peripheral
neuropathy (CIPN)
(Fig. 1)